AEterna Zentaris/Keryx's Akt inhibitor starts pivotal trial in colorectal cancer
This article was originally published in Scrip
Executive Summary
AEterna Zentaris has begun a Phase III registration trial testing its potential first-in-class oral Akt inhibitor perifosine (KRX-0401) in refractory advanced colorectal cancer.